联合治疗-话题@MedSci

#联合治疗#

277篇内容 | 4136人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1313841, encodeId=206f131384148, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=AJKD：利妥昔单抗+低剂量环磷酰胺+强的松联合治疗原发性膜性肾病的疗效, objectType=article, longId=221413, objectId=18d1221413ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18d1221413ca, replyNumber=0, likeNumber=118, createdTime=2021-12-03, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18d1221413ca, moduleTitle=AJKD：利妥昔单抗+低剂量环磷酰胺+强的松联合治疗原发性膜性肾病的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18d1221413ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313840, encodeId=f0dc13138408e, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=ASCO2021:阿特珠单抗+贝伐珠单抗联合治疗对不可切除肝癌有益, objectType=article, longId=221028, objectId=979e22102878, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=979e22102878, replyNumber=0, likeNumber=50, createdTime=2021-11-27, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=979e22102878, moduleTitle=ASCO2021:阿特珠单抗+贝伐珠单抗联合治疗对不可切除肝癌有益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=979e22102878)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313839, encodeId=6c86131383941, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Diabetes Obes Metab：每日2次艾塞那肽和达格列净单药或联合治疗对2型糖尿病肥胖患者肾功能标志物的影响, objectType=article, longId=219738, objectId=782b219e38c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=782b219e38c6, replyNumber=0, likeNumber=64, createdTime=2021-11-05, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=782b219e38c6, moduleTitle=Diabetes Obes Metab：每日2次艾塞那肽和达格列净单药或联合治疗对2型糖尿病肥胖患者肾功能标志物的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=782b219e38c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313837, encodeId=e115131383eee, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Antioxidants ：GLP1-RA、SGLT-2i及其联合治疗12个月对2型糖尿病患者氧化和抗氧化生物标志物的影响, objectType=article, longId=219643, objectId=0933219643a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0933219643a0, replyNumber=0, likeNumber=108, createdTime=2021-11-03, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0933219643a0, moduleTitle=Antioxidants ：GLP1-RA、SGLT-2i及其联合治疗12个月对2型糖尿病患者氧化和抗氧化生物标志物的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0933219643a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313838, encodeId=584a131383898, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=AJRCCM：口服曲前列丁尼联合治疗肺动脉高压，一项双盲、安慰剂对照的临床试验, objectType=article, longId=219517, objectId=705a21951e3f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=705a21951e3f, replyNumber=0, likeNumber=68, createdTime=2021-10-31, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=705a21951e3f, moduleTitle=AJRCCM：口服曲前列丁尼联合治疗肺动脉高压，一项双盲、安慰剂对照的临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=705a21951e3f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313836, encodeId=e2681313836a2, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Heart：非维生素K口服抗凝剂和糖皮质激素联合治疗患者的胃肠道出血风险, objectType=article, longId=215986, objectId=4c46215986c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c46215986c9, replyNumber=0, likeNumber=65, createdTime=2021-08-20, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c46215986c9, moduleTitle=Heart：非维生素K口服抗凝剂和糖皮质激素联合治疗患者的胃肠道出血风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4c46215986c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313835, encodeId=b00d13138351c, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Lancet Oncol：乐伐替尼+依托泊苷+异环磷酰胺，复发/难治性骨肉瘤的新联合治疗方案？, objectType=article, longId=215975, objectId=0cf32159e5f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0cf32159e5f1, replyNumber=0, likeNumber=71, createdTime=2021-08-20, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0cf32159e5f1, moduleTitle=Lancet Oncol：乐伐替尼+依托泊苷+异环磷酰胺，复发/难治性骨肉瘤的新联合治疗方案？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0cf32159e5f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313834, encodeId=62bf131383466, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=J Clin Oncol：依西美坦和恩替诺他联合治疗AI耐药的HR阳性、HER2阴性晚期乳腺癌, objectType=article, longId=215465, objectId=b32a2154654f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b32a2154654f, replyNumber=0, likeNumber=87, createdTime=2021-08-10, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b32a2154654f, moduleTitle=J Clin Oncol：依西美坦和恩替诺他联合治疗AI耐药的HR阳性、HER2阴性晚期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b32a2154654f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313833, encodeId=79e713138338e, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Eur J Cancer：帕博西尼、派姆单抗和来曲唑联合治疗HR+转移性乳腺癌的疗效和安全性, objectType=article, longId=214063, objectId=7ac421406392, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ac421406392, replyNumber=0, likeNumber=142, createdTime=2021-07-13, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ac421406392, moduleTitle=Eur J Cancer：帕博西尼、派姆单抗和来曲唑联合治疗HR+转移性乳腺癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7ac421406392)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313832, encodeId=f1731313832e6, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Lung Cancer：EGFR-T790M突变阳性非小细胞肺癌（NSCLC）奥希替尼进展后奥希替尼联合治疗仍有生存获益, objectType=article, longId=213493, objectId=fdd621349391, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdd621349391, replyNumber=0, likeNumber=75, createdTime=2021-07-01, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdd621349391, moduleTitle=Lung Cancer：EGFR-T790M突变阳性非小细胞肺癌（NSCLC）奥希替尼进展后奥希替尼联合治疗仍有生存获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fdd621349391)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313831, encodeId=88bb13138316b, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Lancet子刊 | 我国学者：新型免疫联合治疗大幅延长肝癌患者生存期！, objectType=article, longId=212933, objectId=58b62129339e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58b62129339e, replyNumber=0, likeNumber=68, createdTime=2021-06-21, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58b62129339e, moduleTitle=Lancet子刊 | 我国学者：新型免疫联合治疗大幅延长肝癌患者生存期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58b62129339e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313830, encodeId=3c3413138300e, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Br J Cancer：berzosertib+吉西他滨±顺铂联合治疗晚期实体瘤, objectType=article, longId=212648, objectId=29832126486f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29832126486f, replyNumber=0, likeNumber=66, createdTime=2021-06-13, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29832126486f, moduleTitle=Br J Cancer：berzosertib+吉西他滨±顺铂联合治疗晚期实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29832126486f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313829, encodeId=eb6b131382935, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=ASCO2021:阿特珠单抗+贝伐珠单抗联合治疗对不可切除肝癌有益, objectType=article, longId=212455, objectId=f416212455b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f416212455b8, replyNumber=0, likeNumber=70, createdTime=2021-06-09, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f416212455b8, moduleTitle=ASCO2021:阿特珠单抗+贝伐珠单抗联合治疗对不可切除肝癌有益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f416212455b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313828, encodeId=bfc013138286c, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Br J Cancer：帕唑帕尼与拓扑替康联合治疗转移性和不可切除性软组织肉瘤患者的II期临床研究, objectType=article, longId=212072, objectId=e36e2120e2eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e36e2120e2eb, replyNumber=0, likeNumber=66, createdTime=2021-06-01, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e36e2120e2eb, moduleTitle=Br J Cancer：帕唑帕尼与拓扑替康联合治疗转移性和不可切除性软组织肉瘤患者的II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e36e2120e2eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313827, encodeId=b42f131382eeb, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=肝细胞癌的分子靶向药物与免疫抑制剂联合治疗及其他联合治疗, objectType=article, longId=211270, objectId=a5bb2112e0e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5bb2112e0e5, replyNumber=0, likeNumber=85, createdTime=2021-05-15, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5bb2112e0e5, moduleTitle=肝细胞癌的分子靶向药物与免疫抑制剂联合治疗及其他联合治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a5bb2112e0e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313826, encodeId=9a241313826f7, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Neurology:轻症的脑中风，溶栓和取栓联合治疗效果更好, objectType=article, longId=210629, objectId=13f42106290f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13f42106290f, replyNumber=0, likeNumber=66, createdTime=2021-04-30, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13f42106290f, moduleTitle=Neurology:轻症的脑中风，溶栓和取栓联合治疗效果更好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=13f42106290f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313825, encodeId=200213138258e, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=CHMP建议批准Sarclisa（isatuximab）与卡非佐米和地塞米松联合治疗复发性多发性骨髓瘤, objectType=article, longId=207705, objectId=73c620e7058a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73c620e7058a, replyNumber=0, likeNumber=80, createdTime=2021-03-01, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73c620e7058a, moduleTitle=CHMP建议批准Sarclisa（isatuximab）与卡非佐米和地塞米松联合治疗复发性多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73c620e7058a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313824, encodeId=a2ca1313824ef, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=NEJM：占诺美林-曲司氯铵联合治疗精神分裂症, objectType=article, longId=207612, objectId=1e5220e612b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e5220e612b9, replyNumber=0, likeNumber=109, createdTime=2021-02-27, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e5220e612b9, moduleTitle=NEJM：占诺美林-曲司氯铵联合治疗精神分裂症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e5220e612b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313823, encodeId=3f4513138233f, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=JCO：来那度胺+R-CHOP联合治疗未能显著改善ABC型DLBCL的PFS, objectType=article, longId=207552, objectId=b86b20e552cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b86b20e552cf, replyNumber=0, likeNumber=74, createdTime=2021-02-26, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b86b20e552cf, moduleTitle=JCO：来那度胺+R-CHOP联合治疗未能显著改善ABC型DLBCL的PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b86b20e552cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313822, encodeId=39d9131382256, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Blood：BH3图谱分析发现ruxolitinib可与ventoclax联合治疗前体T淋巴细胞白血病, objectType=article, longId=207368, objectId=dbc020e368b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbc020e368b8, replyNumber=0, likeNumber=88, createdTime=2021-02-22, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbc020e368b8, moduleTitle=Blood：BH3图谱分析发现ruxolitinib可与ventoclax联合治疗前体T淋巴细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dbc020e368b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

联合治疗

2020-05-29

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

AJKD：利妥昔单抗+低剂量环磷酰胺+强的松联合治疗原发性膜性肾病的疗效

2021-12-03

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

ASCO2021:阿特珠单抗+贝伐珠单抗联合治疗对不可切除肝癌有益

2021-11-27

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Diabetes Obes Metab：每日2次艾塞那肽和达格列净单药或联合治疗对2型糖尿病肥胖患者肾功能标志物的影响

2021-11-05

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Antioxidants ：GLP1-RA、SGLT-2i及其联合治疗12个月对2型糖尿病患者氧化和抗氧化生物标志物的影响

2021-11-03

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

AJRCCM：口服曲前列丁尼联合治疗肺动脉高压，一项双盲、安慰剂对照的临床试验

2021-10-31

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Heart：非维生素K口服抗凝剂和糖皮质激素联合治疗患者的胃肠道出血风险

2021-08-20

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Lancet Oncol：乐伐替尼+依托泊苷+异环磷酰胺，复发/难治性骨肉瘤的新联合治疗方案？

2021-08-20

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

J Clin Oncol：依西美坦和恩替诺他联合治疗AI耐药的HR阳性、HER2阴性晚期乳腺癌

2021-08-10

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Eur J Cancer：帕博西尼、派姆单抗和来曲唑联合治疗HR+转移性乳腺癌的疗效和安全性

2021-07-13

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Lung Cancer：EGFR-T790M突变阳性非小细胞肺癌（NSCLC）奥希替尼进展后奥希替尼联合治疗仍有生存获益

2021-07-01

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Lancet子刊 | 我国学者：新型免疫联合治疗大幅延长肝癌患者生存期！

2021-06-21

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Br J Cancer：berzosertib+吉西他滨±顺铂联合治疗晚期实体瘤

2021-06-13

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

ASCO2021:阿特珠单抗+贝伐珠单抗联合治疗对不可切除肝癌有益

2021-06-09

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Br J Cancer：帕唑帕尼与拓扑替康联合治疗转移性和不可切除性软组织肉瘤患者的II期临床研究

2021-06-01

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

肝细胞癌的分子靶向药物与免疫抑制剂联合治疗及其他联合治疗

2021-05-15

一叶知秋 (审核中...)

前往app查看评论内容

#联合治疗#

Neurology:轻症的脑中风，溶栓和取栓联合治疗效果更好

2021-04-30

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

CHMP建议批准Sarclisa（isatuximab）与卡非佐米和地塞米松联合治疗复发性多发性骨髓瘤

2021-03-01

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

NEJM：占诺美林-曲司氯铵联合治疗精神分裂症

2021-02-27

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

JCO：来那度胺+R-CHOP联合治疗未能显著改善ABC型DLBCL的PFS

2021-02-26

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Blood：BH3图谱分析发现ruxolitinib可与ventoclax联合治疗前体T淋巴细胞白血病

2021-02-22

科室
- - 订阅+
  - 更多科室
工具
服务